Development and characterization of Novel Small Molecule Inhibitors Targeting LAG-3 Protein

Lymphocyte Activation Gene-3 (LAG-3) is a 503-amino acid transmembrane protein that modulates immune responses by negatively regulating the proliferation and activation of T cells - key effectors in adaptive immunity. The finely tuned expression of LAG-3, along with other immune checkpoints, prevents excessive immune activation and safeguards tissues from inflammation-induced damage. Importantly, the immune system also plays a critical role in tumor surveillance by recognizing and eliminating cells expressing neoantigens arising from somatic mutations. However, many cancers exploit immune checkpoint molecules like LAG-3 to dampen antitumor immunity. Elevated expression of LAG-3 within the tumor microenvironment contributes to immune evasion by suppressing cytotoxic T-cell activity. Consequently, inhibition of LAG-3 has emerged as a promising strategy for restoring immune function and enhancing anticancer immunity. This report presents the rational design and development of small-molecule inhibitors targeting LAG-3 through a novel semi-allosteric mechanism - a priori superior to classic (antibody) binding inhibitory - representing a next-generation therapeutic approach with potential applications in oncology and immune-related disorders.